Share Price and Basic Stock Data
Last Updated: December 27, 2025, 9:54 pm
| PEG Ratio | -12.36 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Shalby Ltd operates in the Hospitals & Medical Services sector, with a current market capitalization of ₹2,161 Cr. The company’s revenue trends show a steady increase, with reported sales of ₹805 Cr for the fiscal year ending March 2023, rising to ₹934 Cr for March 2024, and projected to reach ₹1,087 Cr for March 2025. This growth trajectory reflects Shalby’s ability to navigate a challenging healthcare landscape effectively. Quarterly sales figures also indicate a positive trend, with sales rising from ₹201.68 Cr in June 2022 to ₹244.23 Cr by March 2024, peaking at ₹296.43 Cr in June 2025. This consistent growth in sales demonstrates Shalby’s expanding operational capacity and market presence, which is crucial in the competitive healthcare sector. The company’s revenue from operations per share stood at ₹101.12 for March 2025, showcasing an increase from ₹86.93 in March 2024, indicating improved efficiency in generating sales relative to its equity base.
Profitability and Efficiency Metrics
Shalby Ltd’s profitability metrics indicate challenges despite rising revenues. The company reported a net profit of ₹68 Cr for the fiscal year ending March 2023, which fell significantly to only ₹2 Cr in March 2025. This decline is concerning as it reflects a net profit margin of just 0.17% for March 2025, compared to 8.94% in March 2024. Operating profit margins (OPM) also exhibited volatility, standing at 12% for March 2025, down from 21.04% in March 2024. This deterioration in profitability is exacerbated by increasing expenses, which rose from ₹667 Cr in March 2023 to ₹952 Cr in March 2025. Additionally, the interest coverage ratio (ICR) stood at 4.14x, suggesting that while the company can cover its interest obligations, its profitability is under pressure. The cash conversion cycle (CCC) is markedly prolonged at 698 days, indicating inefficiencies in managing working capital and potentially impacting liquidity.
Balance Sheet Strength and Financial Ratios
Shalby Ltd’s balance sheet reflects a mixed picture of financial strength. Total assets stood at ₹1,709 Cr as of March 2025, with total liabilities at ₹1,709 Cr, indicating a balanced leverage position. The company’s borrowings increased to ₹535 Cr, up from ₹476 Cr in the previous year, which raises concerns about its debt levels relative to its equity capital of ₹107 Cr. The return on equity (ROE) was reported at a mere 0.62% for March 2025, highlighting inefficiencies in generating returns for shareholders. Furthermore, the price-to-book value ratio (P/BV) of 2.15x suggests that the stock is trading at a premium compared to its book value, which may deter value-oriented investors. The current ratio of 1.45x indicates that the company can cover its short-term liabilities, but the quick ratio of 0.74x points toward potential liquidity challenges. Overall, while there is an apparent increase in asset base, the growing debt levels and low profitability raise red flags for investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Shalby Ltd indicates a strong promoter backing, with promoters holding 74.33% of the company as of September 2025. This high level of promoter ownership could instill confidence among investors regarding the long-term vision and stability of the company. However, foreign institutional investors (FIIs) hold only 4.63%, which is relatively low compared to industry norms. Domestic institutional investors (DIIs) have a negligible stake of 0.19%, reflecting limited institutional interest in the stock. The public holding stands at 20.18%, suggesting a moderate level of retail investor engagement. The number of shareholders has increased to 53,784, indicating a growing interest in the stock, despite its recent challenges. The dividend payout ratio for March 2025 was reported at 208.30%, reflecting a potential unsustainable distribution policy, given the low net profit, which may raise concerns about the company’s ability to maintain future dividends.
Outlook, Risks, and Final Insight
Shalby Ltd faces a challenging outlook characterized by rising operational costs and declining profitability. The increasing expenses and long cash conversion cycle pose significant risks to its financial health. If the company can streamline its operations and improve cost efficiencies, it may reverse the current trends. On the upside, a sustained increase in patient volumes and a strategic focus on high-margin services could enhance profitability. However, risks such as regulatory changes, competition from established healthcare providers, and economic downturns could impede growth. Investors should remain cautious given the company’s low ROE and high debt levels, balancing these factors against the strong promoter support and potential for operational improvements. A focus on enhancing operational efficiency and managing debt will be critical for Shalby to regain investor confidence and achieve sustainable growth in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.8 Cr. | 134 | 187/120 | 9.14 | 117 | 2.62 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.5 Cr. | 23.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 7.90 Cr. | 7.64 | 20.8/7.08 | 87.8 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.9 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.8 Cr. | 3.67 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,411.86 Cr | 696.56 | 92.72 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 201.68 | 201.80 | 202.46 | 198.98 | 235.49 | 237.98 | 216.05 | 244.23 | 278.89 | 267.54 | 275.63 | 264.89 | 296.43 |
| Expenses | 161.62 | 164.73 | 168.65 | 173.32 | 192.36 | 185.26 | 173.73 | 205.37 | 233.68 | 234.89 | 241.72 | 244.05 | 254.90 |
| Operating Profit | 40.06 | 37.07 | 33.81 | 25.66 | 43.13 | 52.72 | 42.32 | 38.86 | 45.21 | 32.65 | 33.91 | 20.84 | 41.53 |
| OPM % | 19.86% | 18.37% | 16.70% | 12.90% | 18.32% | 22.15% | 19.59% | 15.91% | 16.21% | 12.20% | 12.30% | 7.87% | 14.01% |
| Other Income | 3.99 | 5.31 | 4.19 | 9.18 | 4.53 | 5.38 | 4.52 | 4.99 | 9.70 | 7.16 | 5.42 | 5.32 | 7.01 |
| Interest | 1.84 | 1.79 | 2.67 | 2.84 | 2.75 | 3.17 | 3.63 | 6.47 | 8.12 | 9.26 | 10.66 | 10.67 | 9.37 |
| Depreciation | 11.58 | 11.90 | 11.79 | 12.81 | 11.94 | 12.30 | 12.40 | 15.60 | 16.37 | 16.84 | 16.32 | 16.23 | 16.52 |
| Profit before tax | 30.63 | 28.69 | 23.54 | 19.19 | 32.97 | 42.63 | 30.81 | 21.78 | 30.42 | 13.71 | 12.35 | -0.74 | 22.65 |
| Tax % | 34.38% | 35.83% | 35.09% | 27.57% | 36.85% | 35.30% | 38.14% | 26.35% | 51.55% | 82.71% | 124.21% | 1,547.30% | 66.09% |
| Net Profit | 20.11 | 18.40 | 15.28 | 13.90 | 20.82 | 27.57 | 19.06 | 16.04 | 14.74 | 2.36 | -2.99 | -12.19 | 7.68 |
| EPS in Rs | 1.86 | 1.70 | 1.42 | 1.29 | 1.93 | 2.55 | 1.77 | 1.54 | 1.45 | 0.31 | -0.17 | -1.02 | 0.83 |
Last Updated: August 20, 2025, 3:55 am
Below is a detailed analysis of the quarterly data for Shalby Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 296.43 Cr.. The value appears strong and on an upward trend. It has increased from 264.89 Cr. (Mar 2025) to 296.43 Cr., marking an increase of 31.54 Cr..
- For Expenses, as of Jun 2025, the value is 254.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 244.05 Cr. (Mar 2025) to 254.90 Cr., marking an increase of 10.85 Cr..
- For Operating Profit, as of Jun 2025, the value is 41.53 Cr.. The value appears strong and on an upward trend. It has increased from 20.84 Cr. (Mar 2025) to 41.53 Cr., marking an increase of 20.69 Cr..
- For OPM %, as of Jun 2025, the value is 14.01%. The value appears strong and on an upward trend. It has increased from 7.87% (Mar 2025) to 14.01%, marking an increase of 6.14%.
- For Other Income, as of Jun 2025, the value is 7.01 Cr.. The value appears strong and on an upward trend. It has increased from 5.32 Cr. (Mar 2025) to 7.01 Cr., marking an increase of 1.69 Cr..
- For Interest, as of Jun 2025, the value is 9.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.67 Cr. (Mar 2025) to 9.37 Cr., marking a decrease of 1.30 Cr..
- For Depreciation, as of Jun 2025, the value is 16.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.23 Cr. (Mar 2025) to 16.52 Cr., marking an increase of 0.29 Cr..
- For Profit before tax, as of Jun 2025, the value is 22.65 Cr.. The value appears strong and on an upward trend. It has increased from -0.74 Cr. (Mar 2025) to 22.65 Cr., marking an increase of 23.39 Cr..
- For Tax %, as of Jun 2025, the value is 66.09%. The value appears to be improving (decreasing) as expected. It has decreased from 1,547.30% (Mar 2025) to 66.09%, marking a decrease of 1,481.21%.
- For Net Profit, as of Jun 2025, the value is 7.68 Cr.. The value appears strong and on an upward trend. It has increased from -12.19 Cr. (Mar 2025) to 7.68 Cr., marking an increase of 19.87 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.83. The value appears strong and on an upward trend. It has increased from -1.02 (Mar 2025) to 0.83, marking an increase of 1.85.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 259 | 275 | 290 | 324 | 378 | 462 | 487 | 431 | 699 | 805 | 934 | 1,087 | 1,122 |
| Expenses | 196 | 207 | 235 | 252 | 299 | 379 | 404 | 342 | 577 | 667 | 755 | 952 | 984 |
| Operating Profit | 63 | 68 | 56 | 71 | 79 | 83 | 83 | 89 | 122 | 138 | 179 | 135 | 138 |
| OPM % | 24% | 25% | 19% | 22% | 21% | 18% | 17% | 21% | 17% | 17% | 19% | 12% | 12% |
| Other Income | 2 | 2 | 2 | 7 | 10 | 9 | 17 | 8 | 8 | 22 | 19 | 28 | 22 |
| Interest | 2 | 5 | 10 | 11 | 12 | 9 | 7 | 5 | 8 | 11 | 18 | 41 | 40 |
| Depreciation | 11 | 21 | 11 | 17 | 23 | 33 | 36 | 37 | 43 | 48 | 52 | 66 | 66 |
| Profit before tax | 52 | 43 | 36 | 50 | 54 | 50 | 57 | 55 | 79 | 102 | 128 | 56 | 53 |
| Tax % | 28% | 43% | -1% | 43% | 27% | 37% | 51% | 23% | 32% | 34% | 35% | 97% | |
| Net Profit | 38 | 25 | 36 | 29 | 39 | 32 | 28 | 42 | 54 | 68 | 84 | 2 | -0 |
| EPS in Rs | 11.17 | 7.36 | 4.30 | 3.40 | 3.65 | 2.93 | 2.55 | 3.93 | 5.01 | 6.27 | 7.78 | 0.58 | 0.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 17% | 20% | 25% | 20% | 19% | 15% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -34.21% | 44.00% | -19.44% | 34.48% | -17.95% | -12.50% | 50.00% | 28.57% | 25.93% | 23.53% | -97.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 78.21% | -63.44% | 53.93% | -52.43% | 5.45% | 62.50% | -21.43% | -2.65% | -2.40% | -121.15% |
Shalby Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 17% |
| 3 Years: | 16% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -26% |
| 3 Years: | -52% |
| TTM: | -101% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 12% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 35 | 35 | 87 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 107 | 108 |
| Reserves | 106 | 133 | 117 | 164 | 643 | 672 | 691 | 727 | 768 | 820 | 893 | 885 | 895 |
| Borrowings | 37 | 98 | 224 | 328 | 114 | 71 | 62 | 44 | 155 | 180 | 378 | 476 | 535 |
| Other Liabilities | 39 | 85 | 75 | 99 | 96 | 89 | 105 | 118 | 162 | 173 | 231 | 241 | 246 |
| Total Liabilities | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,782 |
| Fixed Assets | 130 | 175 | 319 | 323 | 650 | 692 | 672 | 660 | 675 | 685 | 966 | 955 | 976 |
| CWIP | 5 | 91 | 82 | 221 | 47 | 3 | 6 | 8 | 6 | 11 | 15 | 22 | 54 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 28 | 16 | 25 | 146 | 81 | 95 | 87 |
| Other Assets | 81 | 85 | 102 | 134 | 264 | 233 | 260 | 314 | 488 | 440 | 547 | 637 | 665 |
| Total Assets | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,782 |
Below is a detailed analysis of the balance sheet data for Shalby Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 108.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 895.00 Cr.. The value appears strong and on an upward trend. It has increased from 885.00 Cr. (Mar 2025) to 895.00 Cr., marking an increase of 10.00 Cr..
- For Borrowings, as of Sep 2025, the value is 535.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 476.00 Cr. (Mar 2025) to 535.00 Cr., marking an increase of 59.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 241.00 Cr. (Mar 2025) to 246.00 Cr., marking an increase of 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,782.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,709.00 Cr. (Mar 2025) to 1,782.00 Cr., marking an increase of 73.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 976.00 Cr.. The value appears strong and on an upward trend. It has increased from 955.00 Cr. (Mar 2025) to 976.00 Cr., marking an increase of 21.00 Cr..
- For CWIP, as of Sep 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 54.00 Cr., marking an increase of 32.00 Cr..
- For Investments, as of Sep 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 95.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 665.00 Cr.. The value appears strong and on an upward trend. It has increased from 637.00 Cr. (Mar 2025) to 665.00 Cr., marking an increase of 28.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,782.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,709.00 Cr. (Mar 2025) to 1,782.00 Cr., marking an increase of 73.00 Cr..
Notably, the Reserves (895.00 Cr.) exceed the Borrowings (535.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 26.00 | -30.00 | -168.00 | -257.00 | -35.00 | 12.00 | 21.00 | 45.00 | -33.00 | -42.00 | -199.00 | -341.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 29 | 40 | 38 | 49 | 64 | 71 | 80 | 53 | 48 | 57 | 59 |
| Inventory Days | 77 | 113 | 119 | 105 | 242 | 1,152 | 1,361 | 1,017 | ||||
| Days Payable | 395 | 462 | 522 | 415 | 606 | 546 | 744 | 377 | ||||
| Cash Conversion Cycle | 21 | 29 | 40 | -280 | -299 | -339 | -239 | -283 | 53 | 654 | 673 | 698 |
| Working Capital Days | 35 | -46 | -26 | -64 | -18 | 57 | 70 | 77 | 74 | 75 | 48 | 56 |
| ROCE % | 22% | 13% | 12% | 9% | 7% | 7% | 7% | 10% | 10% | 11% | 7% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 287 | 0.09 | 0.01 | 287 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.18 | 7.78 | 6.31 | 5.00 | 3.92 |
| Diluted EPS (Rs.) | 0.18 | 7.77 | 6.27 | 5.00 | 3.92 |
| Cash EPS (Rs.) | 6.30 | 12.64 | 10.79 | 8.97 | 7.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 92.31 | 93.82 | 86.44 | 81.13 | 77.28 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 92.31 | 93.82 | 86.44 | 81.13 | 77.28 |
| Revenue From Operations / Share (Rs.) | 101.12 | 86.93 | 75.01 | 64.72 | 39.90 |
| PBDIT / Share (Rs.) | 14.90 | 18.29 | 14.84 | 12.26 | 8.84 |
| PBIT / Share (Rs.) | 8.79 | 13.43 | 10.36 | 8.29 | 5.43 |
| PBT / Share (Rs.) | 5.18 | 11.93 | 9.51 | 7.33 | 5.10 |
| Net Profit / Share (Rs.) | 0.17 | 7.77 | 6.31 | 5.00 | 3.92 |
| NP After MI And SOA / Share (Rs.) | 0.57 | 7.83 | 6.31 | 5.01 | 3.92 |
| PBDIT Margin (%) | 14.73 | 21.04 | 19.78 | 18.93 | 22.15 |
| PBIT Margin (%) | 8.68 | 15.44 | 13.81 | 12.80 | 13.61 |
| PBT Margin (%) | 5.12 | 13.72 | 12.67 | 11.32 | 12.77 |
| Net Profit Margin (%) | 0.17 | 8.94 | 8.40 | 7.72 | 9.83 |
| NP After MI And SOA Margin (%) | 0.57 | 9.00 | 8.41 | 7.74 | 9.83 |
| Return on Networth / Equity (%) | 0.62 | 8.40 | 7.29 | 6.17 | 5.07 |
| Return on Capital Employeed (%) | 7.56 | 11.22 | 10.22 | 8.76 | 6.41 |
| Return On Assets (%) | 0.36 | 5.23 | 5.28 | 4.53 | 4.25 |
| Long Term Debt / Equity (X) | 0.13 | 0.17 | 0.07 | 0.09 | 0.04 |
| Total Debt / Equity (X) | 0.43 | 0.31 | 0.15 | 0.17 | 0.04 |
| Asset Turnover Ratio (%) | 0.65 | 0.64 | 0.59 | 0.62 | 0.42 |
| Current Ratio (X) | 1.45 | 1.71 | 2.66 | 2.61 | 3.32 |
| Quick Ratio (X) | 0.74 | 0.98 | 1.71 | 1.91 | 3.04 |
| Inventory Turnover Ratio (X) | 3.92 | 0.15 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 208.30 | 15.41 | 15.95 | 19.95 | 12.73 |
| Dividend Payout Ratio (CP) (%) | 18.00 | 9.50 | 9.32 | 11.13 | 6.81 |
| Earning Retention Ratio (%) | -108.30 | 84.59 | 84.05 | 80.05 | 87.27 |
| Cash Earning Retention Ratio (%) | 82.00 | 90.50 | 90.68 | 88.87 | 93.19 |
| Interest Coverage Ratio (X) | 4.14 | 12.25 | 17.44 | 22.43 | 26.38 |
| Interest Coverage Ratio (Post Tax) (X) | 1.05 | 6.21 | 8.41 | 10.90 | 12.71 |
| Enterprise Value (Cr.) | 2524.31 | 2864.54 | 1573.71 | 1305.75 | 1041.12 |
| EV / Net Operating Revenue (X) | 2.32 | 3.07 | 1.96 | 1.87 | 2.42 |
| EV / EBITDA (X) | 15.76 | 14.58 | 9.88 | 9.87 | 10.91 |
| MarketCap / Net Operating Revenue (X) | 1.96 | 2.75 | 1.79 | 1.80 | 2.53 |
| Retention Ratios (%) | -108.30 | 84.58 | 84.04 | 80.04 | 87.26 |
| Price / BV (X) | 2.15 | 2.57 | 1.56 | 1.44 | 1.30 |
| Price / Net Operating Revenue (X) | 1.96 | 2.75 | 1.79 | 1.80 | 2.53 |
| EarningsYield | 0.00 | 0.03 | 0.04 | 0.04 | 0.03 |
After reviewing the key financial ratios for Shalby Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 5. It has decreased from 7.78 (Mar 24) to 0.18, marking a decrease of 7.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 5. It has decreased from 7.77 (Mar 24) to 0.18, marking a decrease of 7.59.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.30. This value is within the healthy range. It has decreased from 12.64 (Mar 24) to 6.30, marking a decrease of 6.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 92.31. It has decreased from 93.82 (Mar 24) to 92.31, marking a decrease of 1.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 92.31. It has decreased from 93.82 (Mar 24) to 92.31, marking a decrease of 1.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 101.12. It has increased from 86.93 (Mar 24) to 101.12, marking an increase of 14.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.90. This value is within the healthy range. It has decreased from 18.29 (Mar 24) to 14.90, marking a decrease of 3.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.79. This value is within the healthy range. It has decreased from 13.43 (Mar 24) to 8.79, marking a decrease of 4.64.
- For PBT / Share (Rs.), as of Mar 25, the value is 5.18. This value is within the healthy range. It has decreased from 11.93 (Mar 24) to 5.18, marking a decrease of 6.75.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 2. It has decreased from 7.77 (Mar 24) to 0.17, marking a decrease of 7.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 2. It has decreased from 7.83 (Mar 24) to 0.57, marking a decrease of 7.26.
- For PBDIT Margin (%), as of Mar 25, the value is 14.73. This value is within the healthy range. It has decreased from 21.04 (Mar 24) to 14.73, marking a decrease of 6.31.
- For PBIT Margin (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 10. It has decreased from 15.44 (Mar 24) to 8.68, marking a decrease of 6.76.
- For PBT Margin (%), as of Mar 25, the value is 5.12. This value is below the healthy minimum of 10. It has decreased from 13.72 (Mar 24) to 5.12, marking a decrease of 8.60.
- For Net Profit Margin (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 8.94 (Mar 24) to 0.17, marking a decrease of 8.77.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 8. It has decreased from 9.00 (Mar 24) to 0.57, marking a decrease of 8.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 15. It has decreased from 8.40 (Mar 24) to 0.62, marking a decrease of 7.78.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.56. This value is below the healthy minimum of 10. It has decreased from 11.22 (Mar 24) to 7.56, marking a decrease of 3.66.
- For Return On Assets (%), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 5. It has decreased from 5.23 (Mar 24) to 0.36, marking a decrease of 4.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.17 (Mar 24) to 0.13, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.43. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.43, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.64 (Mar 24) to 0.65, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has decreased from 1.71 (Mar 24) to 1.45, marking a decrease of 0.26.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.74, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.92. This value is below the healthy minimum of 4. It has increased from 0.15 (Mar 24) to 3.92, marking an increase of 3.77.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 208.30. This value exceeds the healthy maximum of 50. It has increased from 15.41 (Mar 24) to 208.30, marking an increase of 192.89.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 18.00. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 18.00, marking an increase of 8.50.
- For Earning Retention Ratio (%), as of Mar 25, the value is -108.30. This value is below the healthy minimum of 40. It has decreased from 84.59 (Mar 24) to -108.30, marking a decrease of 192.89.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 82.00. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 82.00, marking a decrease of 8.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.14. This value is within the healthy range. It has decreased from 12.25 (Mar 24) to 4.14, marking a decrease of 8.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 3. It has decreased from 6.21 (Mar 24) to 1.05, marking a decrease of 5.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,524.31. It has decreased from 2,864.54 (Mar 24) to 2,524.31, marking a decrease of 340.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.32. This value is within the healthy range. It has decreased from 3.07 (Mar 24) to 2.32, marking a decrease of 0.75.
- For EV / EBITDA (X), as of Mar 25, the value is 15.76. This value exceeds the healthy maximum of 15. It has increased from 14.58 (Mar 24) to 15.76, marking an increase of 1.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has decreased from 2.75 (Mar 24) to 1.96, marking a decrease of 0.79.
- For Retention Ratios (%), as of Mar 25, the value is -108.30. This value is below the healthy minimum of 30. It has decreased from 84.58 (Mar 24) to -108.30, marking a decrease of 192.88.
- For Price / BV (X), as of Mar 25, the value is 2.15. This value is within the healthy range. It has decreased from 2.57 (Mar 24) to 2.15, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has decreased from 2.75 (Mar 24) to 1.96, marking a decrease of 0.79.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Shalby Ltd:
- Net Profit Margin: 0.17%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.56% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.62% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 483 (Industry average Stock P/E: 92.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.43
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.17%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Shalby Multi-Specialty Hospitals, Opp. Karnavati Club, Ahmedabad Gujarat 380015 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Vikram Shah | Chairman & Managing Director |
| Dr. Ashok Bhatia | Independent Director |
| CA. Shyamal Joshi | Independent Director |
| Dr. Umesh Menon | Independent Director |
| Mr. Tej Malhotra | Independent Director |
| CA. Sujana Shah | Independent Director |
| Mr. Vijay Kedia | Independent Director |
FAQ
What is the intrinsic value of Shalby Ltd?
Shalby Ltd's intrinsic value (as of 27 December 2025) is 226.77 which is 13.39% higher the current market price of 200.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 2,163 Cr. market cap, FY2025-2026 high/low of 275/177, reserves of ₹895 Cr, and liabilities of 1,782 Cr.
What is the Market Cap of Shalby Ltd?
The Market Cap of Shalby Ltd is 2,163 Cr..
What is the current Stock Price of Shalby Ltd as on 27 December 2025?
The current stock price of Shalby Ltd as on 27 December 2025 is 200.
What is the High / Low of Shalby Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Shalby Ltd stocks is 275/177.
What is the Stock P/E of Shalby Ltd?
The Stock P/E of Shalby Ltd is 483.
What is the Book Value of Shalby Ltd?
The Book Value of Shalby Ltd is 92.8.
What is the Dividend Yield of Shalby Ltd?
The Dividend Yield of Shalby Ltd is 0.00 %.
What is the ROCE of Shalby Ltd?
The ROCE of Shalby Ltd is 6.12 %.
What is the ROE of Shalby Ltd?
The ROE of Shalby Ltd is 0.62 %.
What is the Face Value of Shalby Ltd?
The Face Value of Shalby Ltd is 10.0.